Skip to main content

NCT00267969 - A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Trial Evaluating the Efficacy and Safety of Ustekinumab (CNTO 1275) in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis

A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Trial Evaluating the Efficacy and Safety of Ustekinumab (CNTO 1275) in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis


Data Specification

Annotated CRF

Available upon data request approval

Product Info

Generic Name
Ustekinumab
Product Name
STELARA®
Therapeutic Area
Skin and Connective Tissue Diseases
Enrollment
766
% Female
30.7%
% White
93.6%
Product Class
Antipsoriatics
Sponsor Protocol Number
C0743T08
Data Partner
Johnson & Johnson
Condition Studied
Psoriasis
Mean/Median Age (Years)
45.5

Supporting Documentation

Clinical Study Report
Collected Datasets
Data Definition Specification
Annotated Case Report Form
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
3

APPROVED DATA REQUESTS ASSOCIATED WITH THIS TRIAL

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.